دورية أكاديمية
أعرض في EDS

Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

التفاصيل البيبلوغرافية
العنوان: Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
المؤلفون: Ondrej Fiala, Jindrich Finek, Alexandr Poprach, Bohuslav Melichar, Jindrich Kopecký, Milada Zemanova, Katerina Kopeckova, Tomas Mlcoch, Tomas Dolezal, Lenka Capkova, Tomas Buchler
المصدر: Cancers, Vol 12, Iss 4, p 808 (2020)
بيانات النشر: MDPI AG, 2020.
سنة النشر: 2020
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: renal cell carcinoma, Memorial Sloan–Kettering Cancer Center risk, sunitinib, first line, outcome, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2072-6694
Relation: https://www.mdpi.com/2072-6694/12/4/808; https://doaj.org/toc/2072-6694
DOI: 10.3390/cancers12040808
URL الوصول: https://doaj.org/article/9f7a13692e81478185495db26714f25d
رقم الأكسشن: edsdoj.9f7a13692e81478185495db26714f25d
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20726694
DOI:10.3390/cancers12040808